Autigen Therapeutics

Autigen Therapeutics is a biotechnology company focused on the development of regenerative therapies for sensorineural hearing loss. The company's primary approach involves the use of small molecule inhibitors to target the Notch signaling pathway, aiming to induce the regeneration of sensory hair cells in the inner ear. Founded on breakthrough research from the University of Southern California and Massachusetts Eye and Ear, Autigen operates through a strategic collaboration with Boehringer Ingelheim. Their research addresses a significant unmet need in otology, as mammalian hair cells do not naturally regenerate after damage or loss.